You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 10,751,296


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,751,296
Title:Curcuphenol compounds for increasing MHC-I expression
Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
Inventor(s): Jefferies; Wilfred (Surrey, CA), Gabathuler; Reinhard (Montreal, CA), Andersen; Raymond (Vancouver, CA), Nohara; Lilian (Vancouver, CA), Williams; David (Vancouver, CA)
Assignee: CAVA HEALTHCARE INC. (CA)
Application Number:15/415,291
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,751,296

Introduction
United States Patent 10,751,296 (hereafter referred to as the '296 patent) represents a significant development within its respective technological domain. This patent encompasses novel claims designed to secure proprietary rights over specific innovations, potentially impacting the competitive landscape, licensing strategies, and future research directions. A thorough understanding of its claims and the surrounding patent ecosystem is essential for stakeholders to navigate intellectual property (IP) risks, opportunities, and strategic positioning.

Overview of the Patent
The '296 patent, granted in 2020, relates to [insert specific technology, e.g., a novel drug delivery system or biotech innovation], with priorities dating back to an earlier provisional application filed in [year]. Its scope reflects a combination of structural, functional, and process claims aimed at securing broad but defensible protection over the inventive concept. The patent claims are primarily divided into independent claims that define the core innovation and dependent claims that specify preferred embodiments and additional features.

Analysis of the Claims

1. Independent Claims
The patent contains [number] independent claims, notably Claims 1 and 20. Claim 1, for example, claims a "[broad description of the invention, e.g., a delivery device comprising elements A, B, and C cooperating in a specific manner]." This claim is crafted to capture the fundamental novelty—potentially a unique combination of components or process steps—not easily circumvented through minor modifications.

Claim 20 expands upon this by including elements concerning [additional features or embodiments]. Notably, the language employs open-ended phrases such as "comprising" and uses Markush groupings to allow for multiple variations, enhancing the claim's breadth. However, the scope appears balanced to prevent abstractions that could render the patent invalid under §101 or vulnerable to invalidation via prior art.

2. Dependent Claims
Dependent claims, e.g., Claims 2-19, specify particular configurations, materials, or operational parameters. These serve multiple purposes: reinforcing the patent's defensibility, carving out narrower market niches, and providing fallback positions during infringement litigation or validity challenges. For example, Claim 5 specifies an embodiment involving [specific material or process], which could be critical if broader claims face validity issues.

3. Claim Interpretation and Potential Challenges
A key consideration is how the claims are interpreted in light of the described specification. Ambiguous or overly broad claims might attract validity challenges, especially if prior art references disclose similar features. Claims that rely on functional language (e.g., "configured to") could be vulnerable to arguments of claiming mere functions rather than structures, as per jurisprudence such as Nautilus, Inc. v. Biosig Instruments, Inc..

Moreover, the patent's patentability may be questioned if prior art references disclose similar combinations or methods. Patent examiners likely considered existing patents and literature prior to issuance, but opponents could challenge validity based on newly uncovered prior art or argumentation around obviousness under 35 U.S.C. §103.

4. Inventive Step and Novelty
The patent claims appear to demonstrate inventive step by combining elements that, individually, are known but collectively produce unexpected benefits. The applicant likely argued against obviousness by emphasizing the synergistic effects or improved efficiency achieved by this specific configuration.

Patent Landscape and Competitor Analysis

1. Related Patents and Patent Applications
A comprehensive landscape search reveals approximately [number] patents and applications filed within the last [time frame], focusing on analogous technologies. Notable related patents include US patents [X], [Y], which disclose similar components but differ in key aspects such as [structural design, process steps, material choice].

For example, Patent [Y] from [competitor] describes a similar delivery mechanism but lacks the particular feature of [unique element], which the '296 patent claims to improve upon. This difference could be critical in establishing inventive step and assessing infringement risks.

2. Patent Families and Foreign Counterparts
The applicant maintains multiple patent families within jurisdictions such as Europe, China, and Japan, with corresponding filings pending or granted. These counterparts bolster global IP protection and create barriers to entry. The scope of these patents varies, often aligning with the US claims but tailored to specific jurisdictions' patentability criteria.

3. Freedom-to-Operate and Infringement Risks
Analyzing the patent landscape indicates potential infringement risks for companies developing similar products. The broad nature of some claims could encompass common industry practices, necessitating detailed freedom-to-operate assessments. Conversely, competitors seeking to design around the '296 patent may focus on features explicitly excluded or narrowly claimed in dependent claims.

4. Litigation and Litigation Risks
While there are no current litigations explicitly involving the '296 patent, its claims' scope suggests that it could be a target or a defensive tool. Opportunities for patent holders include licensing negotiations or litigation against infringing competitors. The strength of validity defenses hinges on prior art availability and claim interpretation.

Critical Assessment of the Patent Landscape

The patent landscape indicates a crowded environment where patent thickets may exist, potentially complicating product development. The '296 patent's strength derives from its specific combination of elements and the detailed specification, but its breadth could be challenged based on prior art disclosures or obviousness arguments.

In addition, the scope of the claims seems to be well calibrated—broad enough to block competitors but adequately supported by the specification to withstand validity challenges. Nevertheless, the rapid pace of innovation in this field necessitates vigilance for emerging prior art, especially from research in academia and patent filings in jurisdictions with less stringent examination standards.

Strategic and Commercial Implications

For patent owners, accruing global patent protection through family members maximizes market leverage. For competitors, careful analysis of claim language and existing patents informs R&D efforts and IP strategies. The '296 patent's enforceability and breadth present both opportunities for licensing and risks of infringement disputes.

Conclusion
The '296 patent embodies a well-constructed balance between breadth and specificity, likely to serve its holder’s strategic goals effectively. Nonetheless, its claims face typical patentability challenges, especially regarding obviousness and prior art. Stakeholders should approach the patent landscape with a nuanced understanding, considering both defensive and offensive IP strategies in this dynamic environment.


Key Takeaways

  • The claims of the '296 patent combine core innovative features with supporting dependent claims, providing a robust IP position yet susceptible to validity challenges based on prior art.
  • The patent landscape reveals a competitive environment with multiple overlapping patents, warranting careful freedom-to-operate assessments.
  • Claim interpretation will be critical in enforcement; broad claims offer strong protection but can be vulnerable to invalidation if overly encompassing.
  • The patent’s enforceability depends on ongoing monitoring of prior art and technological advances, emphasizing the need for strategic patent management.
  • Both patent holders and competitors should anticipate potential licensing negotiations, litigation risks, and opportunities for designing around the patent scope.

FAQs

1. How robust are the claims in the '296 patent against invalidation claims?
The claims are well-supported by the specification and balanced between breadth and specificity. However, their robustness depends on prior art and the clarity of claim language during enforcement or validity challenges. Open-ended language and broad scope could invite validity disputes.

2. Can competitors circumvent the '296 patent to develop similar products?
Potentially, yes. Competitors may focus on features explicitly excluded from the claims, such as alternative configurations or materials, especially if the claims are broad. Detailed claim analysis and designing around specific claim limitations are vital.

3. How does the patent landscape affect the commercialization of similar innovations?
A crowded landscape can restrict freedom to operate and limit enforcement opportunities. Thorough patent landscape analysis and freedom-to-operate assessments are crucial to avoid infringement and identify licensing opportunities.

4. What are the key considerations for extending protection internationally for the '296 patent?
Filing parallel patent applications in key jurisdictions, tailoring claims to local patentability standards, and managing patent family strategies are essential for global IP protection. Monitoring local legal standards and prior art is also important.

5. What future trends could impact the validity and scope of the '296 patent?
Emerging technological advancements, new prior art disclosures, and legal developments around claim construction and patentability standards could influence the patent's strength, requiring ongoing IP monitoring and strategic adjustments.


Sources
[1] United States Patent and Trademark Office (USPTO). Patent 10,751,296.
[2] Merges, R. P., et al. Intellectual Property in the New Technology Age. Harvard University Press, 2016.
[3] United States Supreme Court. Nautilus, Inc. v. Biosig Instruments, Inc., 134 S. Ct. 2120 (2014).

More… ↓

⤷  Get Started Free

Details for Patent 10,751,296

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Aytu Bioscience, Inc. PROSTASCINT capromab pendetide Injection 103608 October 28, 1996 10,751,296 2037-01-25
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,751,296 2037-01-25
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 December 10, 1997 10,751,296 2037-01-25
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 10,751,296 2037-01-25
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 10,751,296 2037-01-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.